Pure Organica's fields of action

Medical

Early diagnosis and therapeutic devices: health is the first of our fields.

From the portfolio · Medical · Early detection

Oncotech

Early detection within everyone's reach
«Early detection saves lives — if it reaches everyone.»

Cancer causes nearly 10 million deaths a year and diagnoses will grow 77% by 2050 (WHO). Early detection saves lives, but screening remains costly, invasive and unevenly distributed — precisely where the risk is highest.

Oncotech is developing an iris-scan technology for a pre-screening that is affordable and non-invasive, able to identify early indicators of the most common cancers.

The scan
The iris and pupil measurements
The iris
A single image of the eye
Ophtascan™
AI on a smartphone photo
30 seconds
No blood, no biopsy
Anywhere
From hospitals to remote clinics
Request information
Program under development with Nordic partners; the regulatory path follows the medical-device rules of the target markets.
From the current site — the facts

Ophtascan™

AI reads an iris image captured with a smartphone: it identifies early signs of lung, breast, cervical, uterine, prostate and colon cancers — and of type 2 diabetes.

First in Europe

First technology in Europe clinically tested and validated for real-time, on-demand cancer screening.

Portable

Lightweight and usable anywhere: from European hospitals to the most remote clinics, with no dedicated infrastructure.

The numbers

~10 million deaths in 2020 · 35 million diagnoses expected by 2050 · +77% versus 2022 (WHO).

Market and certifications — from the current site

CE Class I

CE mark obtained and clinical validation in Europe; awaiting multi-site clinical data, with expansion toward the US market.

Results in 30 seconds

Iris-pattern reading in under half a minute: non-invasive, in real time, anywhere in the world.

Scalable platform

Beyond oncology: the same technology identifies indicators of type 2 diabetes and other systemic conditions.

The certifications

STED · CE Class 1 · MedAidUK — a strategic opportunity in a large unmet-need category.

A technology of the Pure Organica Corp. portfolio
Genesi MED 3
From the portfolio · Medical · Electromedical

GENESI MED 3

Radiofrequency at the service of therapy
«Three channels, one platform: energy dosed where it is needed.»

Genesi MED 3 is a multichannel medical radiofrequency generator developed in Italy: three independent channels, dedicated antennas and integrated patient management for therapeutic and rehabilitative applications.

The platform is born from the group's experience in medical devices and keeps its entire technical heritage in-house: design, electronics and application software.

Three channels
The touch interface at work
Antennas
The shaped flexible applicator
Software
Integrated patient management
Made in Italy
The Zannini-branded front panel
The product site →Request information
A product of Zannini Gemini S.r.l. (Pisa), a group company; exclusive partner Pure Organica Corp. With the same technology, now under study and development: Genesi VET 3, for animals with chronic conditions. Medical device CE marked; FDA registration filed for the US market.
A technology of the Pure Organica Corp. portfolio